Loading clinical trials...
Loading clinical trials...
Multicenter, randomized (2:1), open-label phase 3 study in HLA-A2 positive patients with squamous and non-squamous metastatic NSCLC with ICI secondary resistance. Patients will be randomized into 2 a...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
OSE Immunotherapeutics
Collaborators
NCT04182698 · Patients With Non-small Cell Lung Cancer
NCT02283320 · KRAS Positive Patients With Non-small Cell Lung Cancer, Squamous Cell Non-small Cell Lung Cancer
NCT01193829 · Patients With Non-small Cell Lung Cancer
Clinical Research Advisors, LLC
Beverly Hills, California
Clinical Research Advisors - Encino
Encino, California
Clinical Research Advisors - West Hollywood
Los Angeles, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions